ClinicalTrials.gg
CompletedNCT04923594Updated Aug 12, 2022

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

A Phase 2 interventional study of mazindol extended release and Placebo in Narcolepsy, Excessive Daytime Sleepiness and Cataplexy Narcolepsy, sponsored by NLS Pharmaceutics. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by NLS Pharmaceutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.
Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-weeks.

02

Conditions studied

  • Narcolepsy
  • Excessive Daytime Sleepiness
  • Cataplexy Narcolepsy
03

In context

Narcolepsy

157 studies on the registry are indexed under Narcolepsy; 37 are open to participants now.

This study's enrollment of 67 is below the median of 78 across 114 interventional studies indexed under Narcolepsy.

Browse Narcolepsy studies →

Lead sponsor

NLS Pharmaceutics is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females between 18 and 65 years of age, inclusive
  • Diagnosis of narcolepsy according to ICSD-3 (International Classification of Sleep Disorders, 3rd Edition) or , 5th Edition (DSM-5) criteria
  • from 18 to 40 kg/m2, inclusive
  • Consent to use a medically acceptable method of
  • Willing and able to provide written

Key Exclusion Criteria:

  • Female subjects who are pregnant, nursing, or lactating
  • Any other medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
  • History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
  • Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
  • Use of any medications that could affect the evaluation of cataplexy
  • Received an drug in the past 30 days or five half-lives (whichever is longer)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    NLS-2 (mazindol extended release)

    2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)

    Drug: mazindol extended release

  • Placebo comparator
    Placebo

    Dosed orally, once daily for up to 4 weeks

    Drug: Placebo

Interventions

  • Dosed orally, once daily for up to 3 weeks

    Also known as: NLS-2

  • DrugPlacebo

    Dosed orally, once daily for up to 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change in ESS Score From Baseline to Week 4

    Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 4. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 4

    Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 4. PGIc is rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse

    Time frame: Baseline to Week 4

07

Study locations

22 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Stanford Sleep Medicine Center
    Redwood City, California 94063, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • St. Francis Sleep Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • The Angel Medical Research Corporation
    Miami Lakes, Florida 33016, United States
  • Sleep Medicine Specialists of South Florida
    Miami, Florida 33126, United States
  • Ivetmar Medical Group
    Miami, Florida 33155, United States
  • Treken Primary care
    Atlanta, Georgia 30315, United States
  • NeuroTrials Research
    Atlanta, Georgia 30328, United States
  • Clinical Research Institute
    Stockbridge, Georgia 30281, United States
  • Hawaii Pacific Neuroscience Clinical Research Center
    Honolulu, Hawaii 96817, United States
  • The Center For Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Sleep and Attention Disorders
    Sterling Heights, Michigan 48314, United States
  • Neurology and Sleep Disorders Clinic
    Columbia, Missouri 65212, United States
  • Carolinas Sleep Specialists
    Concord, North Carolina 28025, United States
  • Superior Clinical Research, LLC
    Goldsboro, North Carolina 27534, United States
  • Advanced Respiratory and Sleep Medicine
    Huntersville, North Carolina 28078, United States
  • Intrepid Research
    Cincinnati, Ohio 45245, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
  • Bogan Sleep Consultants
    Columbia, South Carolina 29201, United States
  • Dharma PA d/b/a Southwest Family Medicine Associates
    Dallas, Texas 75235, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2022, 9 months.

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jun 11, 2021
StartActual
Sep 13, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04923594
Lead sponsor
NLS Pharmaceutics
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Sep 13, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Aug 12, 2022

Study contacts

Carlos Camozzi, MD
study director · NLS Pharmaceutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazindol

Start the discussion